2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells

Hormones and Cancer

Volumn 1, Issue 3, 2010, Pages 117-126

  Quezada, Marisol ^a   Diaz, Jorge ^a   Henriquez, Soledad ^a   Bravo, Maria Loreto ^a   Aranda, Evelyn ^a   Oliva, Barbara ^a   Villalon, Manuel ^a   Kato, Sumie ^a   Cuello, Mauricio A ^a   Brosens, Jan J ^b   Lange, Carol A ^c   Owen, Gareth I ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

2 Methoxyestradiol; Breast cancer; Progesterone receptor; STAT5; Tissue factor

Indexed keywords

2 METHOXYESTRADIOL; BETA ACTIN; ESTRADIOL; ESTROGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROGESTERONE; PROGESTERONE RECEPTOR; STAT5 PROTEIN; THROMBOPLASTIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOPLASTIN; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUBULIN MODULATORS;

EID: 77955550727     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0019-5     Document Type: Article

References (51)

1. Zhu B, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19(1): 1-27.
2. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2: 16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11(6): 635-640.
3. van Zijl C, Lottering ML, Steffens F, Joubert A (2008) In vitro effects of 2-methoxyestradiol on MCF-12A and MCF-7 cell growth, morphology and mitotic spindle formation. Cell Biochem Funct 26(5): 632-642.
4. Mooberry SL (2003) New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15(6): 425-430.
5. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5(1): 22-27.
6. Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C (2009) Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 115(1): 90-96.
7. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR (2010) "A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer". Invest New Drugs.
8. Agoston GE, Shah JH, Suwandi L, Hanson AD, Zhan X, LaVallee TM, Pribluda V, Treston AM (2009) Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol. Bioorg Med Chem Lett 19(21): 6241-6244.
9. Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, Purohit A, Reed MJ (2007) In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 96(9): 1368-1376.
10. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ (2000) 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19(1-2): 173-179.
11. Kato S, Sadarangani A, Lange S, Delpiano AM, Vargas M, Brañes J, Carvajal J, Lipkowitz S, Owen GI y Cuello MA (2008) "2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts". Reprod Sci (9): 878-894.
12. Mulac-Jericevic B, Conneely OM (2005) "Reproductive tissue-selective actions of progesterone receptors". Ernst Schering Res Found Workshop (52): 19-37.
13. Owen GI, Zelent A (2000) Origins and evolutionary diversification of the nuclear receptor superfamily. Cell Mol Life Sci 57(5): 809-827.
14. Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP (2008) The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids 73(9-10): 922-928.
15. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB (1998) Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273(17): 10696-10701.
16. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB (1998) Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273(47): 31317-31326.
17. Lange CA (2008) Integration of progesterone receptor action with rapid signaling events in breast cancer models. J Steroid Biochem Mol Biol 108: 203-212.
18. Gellersen B, Fernandes MS, Brosens JJ (2009) Non-genomic progesterone actions in female reproduction. Hum Reprod Updat 15(1): 119-138, Epub 2008 Oct 19.
19. Qiu M, Lange CA (2003) MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol 85(2-5): 147-157.
20. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382): 419-27.
21. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 289(24): 3243-53.
22. Nualart F, Los Angeles García M, Medina RA, Owen GI (2009) Glucose transporters in sex steroid hormone related cancer. Curr Vasc Pharmacol 7(4): 534-548.
23. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, Horwitz KB, Owen GI (2005) Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab 90(2): 1181-1188.
24. Medina RA, Meneses AM, Vera JC, Gúzman C, Nualart F, Rodriguez F, de los Angeles Garcia M, Kato S, Espinoza N, Monsó C, Carvajal A, Pinto M, Owen GI (2004) Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol 182(3): 467-78.
25. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP (2001) Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 86(1): 334-345.
26. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) "Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells". J Biol Chem 15; 277(7): 5209-18.
27. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10(5): 502-509.
28. Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H (2006) Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 12(13): 4055-4061.
29. Kasthuri RS, Tauban MB, Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol 27(29): 4834-4838.
30. Hu T, Bach RR, Horton R, Konigsberg WH, Todd MB (1994) Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol Res 6(7): 321-327.
31. Bluff JE, Brown NJ, Reed MW, Staton CA (2008) Tissue factor, angiogenesis and tumour progression. Breast Cancer Res 10(2): 204.
32. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Bravo L, Villalon M, Cuello M, Quest AF, Suenaga A, Brosens JJ, Owen GI (2005) Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost 94(2): 444-453.
33. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG (2005) 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res 11(5): 1722-1732.
34. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J, Jackson EK (2000) Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun 278(1): 27-33.
35. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB (1994) "New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP". Cancer Res, 15; 54(14): 3868-77.
36. Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI (2005) Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. Breast Cancer Res Treat 94(2): 171-183.
37. Seger R, Krebs EG (1995) The MAPK signaling cascade. FASEB J 9(9): 726-735.
38. Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13(6): 829-836.
39. Pierson-Mullany LK, Lange CA (2004) Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 24(24): 10542-10557.
40. Aranda E, Owen GI (2009) A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA. hy926 endothelial cell line. Biol Res 42: 377-389.
41. Stander BA, Marais S, Vorster CJ, Joubert AM (2010) In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J Steroid Biochem Mol Biol 119(3-5): 149-160.
42. Fukui M, Zhu B-T (2009) Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Mol Carcinog 48: 66-78.
43. Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, Leese MP, Potter BV, Reed MJ, Purohit A (2006) The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 66(1): 324-330.
44. Ting CM, Lee YM, Wong CK, Wong AS, Lung HL, Lung ML, Lo KW, Wong RN, Mak NK. "2-Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways". Biochem Pharmacol. 2009 Oct 31.
45. Roswall P, Bu S, Rubin K, Landström M, Heldin NE (2006) 2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells. Thyroid 16(2): 143-150.
46. Ray G, Dhar G, van Veldhuizen PJ, Banerjee S, Saxena NK, Sengupta K, Banerjee SK (2006) Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 45(11): 3703-3713.
47. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 8: 206.
48. Kar S, Wang M, Carr BI (2008) 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 62(5): 831-840.
49. Salama SA, Kamel MW, Botting S, Salih SM, Borahay MA, Hamed AA, Kilic GS, Saeed M, Williams MY, Diaz-Arrastia CR (2009) Catechol-o-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. PLoS ONE 4(10): e7356.
50. Faivre EJ, Daniel AR, Hillard CJ, Lange CA (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22(4): 823-837.
51. Berg D, Sonsalla R, Kuss E (1983) Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh) 103(2): 282-288.